EMC: EV 323740595 US

It is claimed:

- 1) A pharmaceutical composition comprising:
 - . (i) at least one halogenated compound, and
- (ii) at least one N-halogenated derivative of at least one compound selected from zwitterionic and/or amino acid compounds,

wherein the composition does not generate substantial stimulation of myeloperoxidase activity in a mammal.

- 2) A pharmaceutical composition according to claim 1, wherein halogens of (i) the halogenated compound and (ii) the N-halogenated derivative, which may be the same or different, are selected from the group consisting of fluorine, iodine, bromine and chlorine.
- 3) A pharmaceutical composition according to claim 1, wherein (i) the halogenated compound is a hypochlorite of an alkaline metal.
- 4) A pharmaceutical composition according to claim 3, wherein the hypochlorite is sodium hypochlorite.
- 5) A pharmaceutical composition according to claim 1, wherein (ii) the N-halogenated derivative is an N-halogen derivative of taurine.
- 6) A pharmaceutical composition according to claim 5, wherein the taurine is taurine N-haloamine.

- 7) A pharmaceutical composition according to claim 5, wherein the taurine is taurine N-chloramine.
- 8) A pharmaceutical composition according to claim 4, wherein the sodium hypochlorite concentration is between about 1 mole/liter and about 1 picomole/liter of available chlorine.
- 9) A pharmaceutical composition according to claim 7, wherein the concentration of the taurine N-chloramine is between about 5 moles/liter and about 0.01 femtomoles/liter.
- 10) A pharmaceutical composition according to claim 1, wherein both (i) the halogenated compound and (ii) the N-halogenated derivative are mixed in with a pharmaceutically acceptable excipient.
- 11) A pharmaceutical composition according to claim 1, further comprising a pharmaceutically compatible agent which modifies at least one physicochemical property of the composition selected from the group consisting of stability, pH, pKa, density, solubility, viscosity, coloring, water/ectanol sharing factor, and surface-active, oxidative, olfactory, or gustatory properties.
- 12) A method of preparing a pharmaceutical composition comprising mixing:
 - (i) at least one halogenated compound,
- (ii) at least one N-halogenated derivative of at least one compound selected from zwitterionic compounds and/or amino acids or their derivatives, and
 - (iii) optionally at least one pharmaceutically acceptable excipient.

A method of preparing a pharmaceutical composition comprising mixing:

at least one halogenated compound, and

at least one zwitterionic compound and/or at least one amino acid or their derivatives, and optionally at least one excipient

to obtain at least one N-halogenated derivative, and at least one halogenated compound in a sufficient therapeutic amount to not substantially stimulate myeloperoxidase activity in a mammal.

- 14) A method according to claim 13, wherein the zwitterionic compound and/or the amino acid is taurine or a taurine analog.
- 15) A method according to claim 13, wherein:
 the halogenated compound is a hypochlorite of alkaline metal, and
 the N-halogenated derivative is N-chlorinated.
- 16) A method according to claim 15, wherein the hypochlorite is sodium hypochorite.
- 17) A method according to claim 15, wherein the N-halogenated derivative is N-chlorinated.
- 18) A method according to claim 16, wherein the concentration of the sodium hypochlorite is between about 6 moles/liter and about 1000.01 femtomoles/liter.
- 19) A method according to claim 14, wherein the concentration of the taurine is between about 5 moles/liter and about 0.01 femtomoles/liter.

20) A method for treatment and/or preventing viral infections, and/or bacterial infections, and/or parasitical infections, and/or fungal infections, and/or diseases generated from non conventional transmissible agents, in humans or animals comprising administring to a human or animal a pharmaceutically effective amount of a pharmaceutical composition comprising:

at least one halogenated compound, and

at least one N-halogenated derivative of at least one compound selected from zwitterionic compounds and/or the amino acids or their derivatives,

without substantial stimulation of myeloperoxidase activity in the human or animal.

21) A method of treating chronic inflammation, and/or progressive inflammation, and/or acute inflammation in humans or animals comprising administering to a human or animal a pharmaceutically effective amount of a pharmaceutical composition comprising:

at least one halogenated compound, and

at least one N-halogenated derivative of at least one compound selected from zwitterionic compounds and/or amino acids or their derivatives,

without substantial stimulation of myeloperoxidase activity in the human or animal.

22) A method of modulating immunity, in humans or animals comprising administering to a human or animal a pharmaceutically effective amount of a pharmaceutical composition comprising:

at least one halogenated compound, and

at least one N-halogenated derivative of at least one compound selected from zwitterionic compounds and/or amino acids or their derivatives,

without substantial stimulatation of myeloperoxidase activity in the human or animal.

23) A method of stimulating tissue healing in humans or animals comprising administering to a human or animal a pharmaceutically effective amount of a pharmaceutical composition comprising:

at least one halogenated compound, and

at least one N-halogenated derivative of at least one compound selected from zwitterionic compounds and/or amino acids or their derivatives, without substantial stimulation of myeloperoxidase activity in the human or animal.

24) A method of pre-surgically, and/or per-surgically, and/or post-surgically irrigating in humans or animals comprising contacting the surgical site with a composition comprising:

at least one halogenated compound, and

at least one N-halogenated derivative of at least one compound selected from zwitterionic compounds and/or amino acids or their derivatives,
without substantial stimulation of myeloperoxidase activity in the human or animal.

- 25) A method according to claim 20, wherein the composition treats lesions and infections linked to periodontitis.
- 26) A method according to claim 20, wherein the composition treats lesions and infections linked to herpesviridiae.